scispace - formally typeset
H

Haitao Yan

Publications -  18
Citations -  234

Haitao Yan is an academic researcher. The author has contributed to research in topics: Receptor & Gating. The author has an hindex of 8, co-authored 16 publications receiving 192 citations.

Papers
More filters
Journal ArticleDOI

External Ba2+ Block of the Two-pore Domain Potassium Channel TREK-1 Defines Conformational Transition in Its Selectivity Filter

TL;DR: It was found that Ba2+ blocked the TREK-1 channel in a concentration- and time-dependent manner and the N-terminal truncated isoform (ΔN41), a product derived from alternative translation initiation, was identified as a constitutively nonconductive variant.
Journal ArticleDOI

Involvement of HCN Channel in Muscarinic Inhibitory Action on Tonic Firing of Dorsolateral Striatal Cholinergic Interneurons

TL;DR: It is reported that muscarinic ACh receptor (M receptor) agonists, ACh and Oxotremorine (OXO-M), decreased the firing frequency of ChIs by blocking the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.
Journal ArticleDOI

Allosteric coupling between proximal C-terminus and selectivity filter is facilitated by the movement of transmembrane segment 4 in TREK-2 channel.

TL;DR: The findings uncover the unique gating properties of TREK-2, and elucidate the mechanisms for how the extracellular and intracellular stimuli harness the pore gating allosterically.
Journal ArticleDOI

Sigma-1 Receptor Plays a Negative Modulation on N-type Calcium Channel

TL;DR: The results revealed that the sigma-1 receptors played a negative modulation on N-type Ca2+ channels and probably involved a chaperone-mediated direct interaction and agonist-induced conformational changes in the receptor-channel complexes on the cell surface.
Journal ArticleDOI

A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1.

TL;DR: R2HBJJ, as a novel mAChRs antagonist, can block the local cholinergic loop by antagonizing predominantly M3 receptors and inhibit NSCLC cell growth, which suggest that M3 receptor antagonist might be a potential chemotherapeutic regimen forNSCLC.